Dr. Rubenstein's research focuses on basic and translational studies of novel means to improve outcomes in cystic fibrosis. He initially focused on correcting the dysfunction of mutant cystic fibrosis transmembrane conductance regulator (CFTR) proteins, which led him to study how molecular chaperones regulate the biogenesis and trafficking of CFTR and other proteins that are relevant to cystic fibrosis.
Dr. Mascarenhas is director of the Nutrition Support Service, section chief of nutrition in the Division of Gastroenterology and Nutrition, medical director of the Clinical Nutrition Department, and director of the Integrative Health Program. Her research interests involve 22q deletion syndrome, cystic fibrosis, nutrition, and integrative medicine.
Dr. Stallings is working on intervention trials involving three chronic diseases with nutrition-related abnormalities resulting in meaningful adverse outcomes: cystic fibrosis (new drugs), sickle cell disease (vitamin A) and chronic pancreatitis (enzyme replacement drug).
Dr. Goldfarb has special interests in the treatment of children with end-stage lung disease such as cystic fibrosis, interstitial lung disease, pulmonary late effects of oncology treatments, and other pulmonary disorders.
Dr. Mayer's research interests center on chronic respiratory failure, the pulmonary manifestations of neuromuscular disease, and assessing and managing patients with complex chest wall and spine disease.
The research interests of Dr. Allen include lung function testing in children, adolescents, and infants; developmental chest wall physiology; pulmonary complications of sickle cell disease; and complications of cystic fibrosis.
Whether they study helmets on the football field or hemophilia in a lab, our scientists at Children’s Hospital of Philadelphia Research Institute are always on the cutting-edge of their respective fields, as the latest roundup of research news shows.